NCT04612907Recruiting
Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
A Randomized Phase III, Multicenter Study to Evaluate Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
Source: ClinicalTrials.gov · Last updated 28 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 420 (estimated)
- First submitted
- 20 Oct 2020
- Start date
- 31 Oct 2022
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Umeå University
- Diseases
- Prostate cancer
- NCT number
- NCT04612907
What you commit to
- Study type: Interventional
- Planned participants: 420
- From 31 Oct 2022 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- High burden metastatic prostate cancer including all with visceral mets.
- Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy
- Radiation treatment start later than nine months after the prostate cancer diagnosis.
Other
- Unable to comply with study procedures.
- Severe micturition problems, IPSS \> 20 ( International Prostate Symptom Score)
Who the study is looking for
- Signed Informed Consent
- Histological confirmed prostate cancer
- Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes
- baseline E-PROM
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancercenter University hospital of Umeå Coordinator of this site? Confirm its status | Umeå | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.